Disposition of the opioid antagonist, nalmefene, in rat and dog

Xenobiotica

Volumn 26, Issue 7, 1996, Pages 779-792

  Murthy, S S ^a   Mathur, C ^a   Kvalo, L T ^a   Lessor, R A ^a   Wilhelm, J A ^a  

^a Ohmeda Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; NALMEFENE; OPIATE ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; LIVER MICROSOME; MALE; NONHUMAN; RAT; URINARY EXCRETION;

EID: 0030055115     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.3109/00498259609046748     Document Type: Article

References (12)

1. BARSAN, W. G., SEGER, D., DANZL, D. F., LING, L. J., BARTLETT, R., BUNCHER, R., and BRYAN, C., 1989, Duration of antagonistic effects of nalmefene and naloxone in opiate-induced sedation for emergency department procedures. American Journal of Emergency Medicine, 7(2), 155-161.
2. BOLLENBECK, G. N., LONG, J. W., BENJAMIN, D. G., and LINDQUIST, J. A., 1955, The synthesis of aryl-D-glucopyranosiduronic acids. Journal of the American Chemical Society, 77, 3310-3315.
3. DIXON, R., HSIAO, J., HSU, H. B., SMULKOWSKI, M., TZE-MING-CHAN, PRAMANIK, B., and MORTON, J., 1989, Isolation of a novel morphinan 3-O-diglucuronide metabolite from dog urine. Pharmaceutical Research, 6(1), 28-32.
4. DYSON, D. H., DOHERTY, T., ANDERSON, G. I., and MCDONELL, W. N., 1990, Reversal of oxymorphone sedation by naloxone, nalmefene and butorphanol. Veterinary Surgery 19(5), 398-403.
5. GAL, T. J., and DIFAZIO, C. A., 1986, Prolonged antagonism of opioid action with intravenous nalmefene in man. Anesthesiology, 64(2), 175-80.
6. GLASS, P. S., JHAVERI, R. M., and SMITH, L. R., 1994, Comparison of potency and duration of action of nalmefene and naloxone. Anesthesia Analgesia, 78, 536-541.
7. KAPLAN, J. L., and MARX, J. A., 1993, Effectiveness and safety of intravenous nalmefene for emergency department patients with suspected narcotic overdose: a pilot study. Annals of Emergency Medicine, 22(2), 187-90.
8. KONIECZKO, K. M., JONES, J. G., BARROWCLIFFE, M. P., JORDAN, C. and ALTMAN, D. G., 1988, Antagonism of morphine-induced respiratory depression with nalmefene. British Journal of Anaesthesiology, 61(3), 318-323.
9. MICHEL, M. E., BOLGER, G., and WEISSMAN, B. A., 1985, Binding of new opiate antagonist, nalmefene to rat brain membranes. Methods and Findings in Experimental Clinical Pharmacology, 7(4), 175-177.
10. VAN VUGT, D. A., WEBB, M. Y., and REID, R. L., 1989, Comparison of the duration of action of nalmefene and naloxone on the hypothalamic pituitary axis of rhesus monkey. Neuroendocrinology, 49, 275-280.
11. VENG-PEDERSEN, P., WILHELM, J. A., ZAKSZEWSKI, T. B., OSIFCHIN, E., and WATERS, S. J., 1995, Duration of opioid antagonism by nalmefene and naloxone in the dog: an integrated pharmacokinetic/pharmacodynamic comparison. Journal of Pharmaceutical Sciences, 84, 1101-1106.
12. WILHELM, J. A., VENG-PEDERSEN, P., ZAKSZEWSKI, T. B., OSIFCHIN, K., and WATERS, S. J., 1995, Duration of opioid antagonism by nalmefene and naloxone in the dog: a nonparametric pharmacodynamic evaluation based on generalized cross-validated spline estimation. International Journal of Clinical Pharmacology and Therapeutics, 33, 540-545.